Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting tags : Pharm-country save search
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
RLYB | News | $1.68 -4.55% -4.76% 350K
|
|
| O: -4.44%
H: 0.0%
C: 0.0%
pharmacy review care meeting
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
URGN | $14.32 0.56% 0.56% 320K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
association for meeting benefits
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.11%
H: 0.38%
C: -0.04%
meeting
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $48.295 0.95% 0.0% 11M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
WGS | $9.565 3.97% 3.82% 160K
|
Professional, Scientific, and T...
|
| O: -1.71%
H: 9.3%
C: 4.65%
meeting
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
OVID | $3.23 3.86% 3.72% 230K
|
Health Technology
|
| O: -1.51%
H: 9.9%
C: 9.04%
meeting therapeutics
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
TARA | $2.705 -0.92% -0.92% 240K
|
Health Technology
|
| O: -2.01%
H: 4.71%
C: -0.68%
tara-002 presentation meeting trial therapeutics
Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
SDGR | $24.37 -2.68% -2.75% 670K
|
Technology Services
|
| O: 7.72%
H: 16.34%
C: 6.47%
sgr-1505 sgr-2921 meeting
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Published: 2023-10-19 (Crawled : 12:00) - biospace.com/
BMY | $48.295 0.95% 0.0% 11M
|
Health Technology
|
| O: -0.37%
H: 0.56%
C: -0.28%
nivolumab renal cell trial
Pyros Pharmaceuticals’ Abstract Accepted for Poster Presentation at the American Epilepsy Society (AES) 2023 Annual Meeting
Published: 2023-10-10 (Crawled : 23:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
| Email alert
Add to watchlist
presentation meeting
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTData Presented at 2023 ASCO Annual Meeting
Published: 2023-06-07 (Crawled : 13:00) - biospace.com/
BYSI | $1.81 -2.16% -2.21% 56K
|
Health Technology
|
| O: 3.2%
H: 2.33%
C: -3.1%
asco cancer meeting
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
Published: 2023-05-09 (Crawled : 13:00) - biospace.com/
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -0.29%
H: 1.97%
C: 0.62%
elacestrant breast asco cancer group meeting
Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting
Published: 2023-05-01 (Crawled : 13:00) - biospace.com/
LIPO | News | $0.706 -5.74% -6.09% 19K
|
|
| O: -6.56%
H: 0.0%
C: -15.35%
association presentation pharmaceuticals meeting
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
Published: 2023-04-28 (Crawled : 13:00) - biospace.com/
ATAI | News | $1.91 -3.54% -3.66% 1M
|
Manufacturing
|
| O: 0.0%
H: 6.15%
C: 2.14%
HTGC F | $18.25 0.5% 0.0% 590K
|
Finance
|
| O: -0.08%
H: 1.25%
C: 0.53%
grx-917 life presentation sciences meeting
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
Published: 2023-04-25 (Crawled : 14:20) - biospace.com/
TGTX | $14.0 1.3% 1.29% 3.5M
|
Health Technology
|
| O: 0.09%
H: 8.17%
C: -1.19%
briumvi presentation sclerosis trials meeting therapeutics
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
Published: 2023-04-24 (Crawled : 12:00) - biospace.com/
APLT A | $4.74 -1.86% -1.9% 720K
|
Health Technology
|
| O: 22.62%
H: 18.97%
C: -5.17%
at-007 fda therapeutics potential kids submission
Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
Published: 2023-04-21 (Crawled : 14:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.53%
H: 0.32%
C: -1.06%
MGTX 4 | $5.02 -4.38% -4.58% 240K
|
Health Technology
|
| O: -0.18%
H: 6.28%
C: 4.81%
association innovation pipeline research meeting
Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting
Published: 2023-04-19 (Crawled : 14:00) - biospace.com/
ATNM | $6.67 -8.0% 0.0% 420K
|
Health Technology
|
| O: -0.86%
H: 1.73%
C: -0.54%
cancer meeting
Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting
Published: 2023-04-19 (Crawled : 14:00) - biospace.com/
ATNM | $6.67 -8.0% 0.0% 420K
|
Health Technology
|
| O: -0.86%
H: 1.73%
C: -0.54%
tumors tumor meeting potential
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
Published: 2023-04-18 (Crawled : 20:00) - biospace.com/
NVCT | $6.725 -0.52% -0.52% 81K
|
|
| O: 0.0%
H: 0.76%
C: 0.76%
nxp800 pharma association presentation cancer research meeting
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.